Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 4/20 | 0.42 |
| ▸ | MLYCD | O95822 | 1/20 | 0.41 |
| ▸ | TACR1 | P25103 | 3/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.40 |
| ▸ | GLS | O94925 | 1/20 | 0.40 |
| ▸ | DDT | P30046 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.39 |
| ▸ | DHODH | Q02127 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29702 | 0.91 | MLYCD (0.43) | CCR1MLYCDTACR1GLSDDT | |
| SCHEMBL29259 | 0.90 | CTNNB1 (0.43) | CCR1TACR1MEN1GAAKMT2A | |
| SCHEMBL30795400 | 0.86 | KDM4E (0.49) | CCR1MLYCDTACR1S1PR3GLS | |
| SCHEMBL20628 | 0.86 | KDM4E (0.49) | CCR1MLYCDTACR1S1PR3GLS | |
| SCHEMBL20313 | 0.86 | MLYCD (0.45) | CCR1MLYCDTACR1GLSMAOB | |
| SCHEMBL22408 | 0.85 | ALDH1A1 (0.46) | CCR1MLYCDTACR1MEN1PLA2G1B | |
| SCHEMBL30039 | 0.85 | MAPK1 (0.43) | CCR1MLYCDTACR1S1PR3GLS | |
| SCHEMBL21439 | 0.85 | KDM4E (0.43) | CCR1MLYCDTACR1S1PR3GLS | |
| SCHEMBL21419 | 0.84 | TACR1 (0.51) | CCR1MLYCDTACR1GLSMAOB | |
| SCHEMBL30478 | 0.84 | MLYCD (0.43) | CCR1MLYCDTACR1GLSMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2609084-A1 | SUBSTITUTED 2-AMINO-QUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2013-07-03 | — | — | EP | claimed |
| US-8470852-B2 | Substituted 2-amino-quinoline-3-carboxamides as KCNQ2/3 modulators | GRUENENTHAL GMBH (DE) | 2013-06-25 | — | — | US | claimed |
| WO-2012025237-A9 | SUBSTITUTED 2-AMINO-QUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2013-02-14 | — | — | WO | claimed |
| US-20120220627-A1 | Substituted 2-amino-quinoline-3-carboxamides as KCNQ2/3 modulators | GRUNENTHAL GMBH (DE) | 2012-08-30 | — | — | US | claimed |
| WO-2012025237-A1 | SUBSTITUTED 2-AMINO-QUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2012-03-01 | — | — | WO | claimed |
| EP-2609084-A1 | SUBSTITUTED 2-AMINO-QUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2013-07-03 | — | — | EP | disclosed |
| US-8470852-B2 | Substituted 2-amino-quinoline-3-carboxamides as KCNQ2/3 modulators | GRUENENTHAL GMBH (DE) | 2013-06-25 | — | — | US | disclosed |
| WO-2012025237-A9 | SUBSTITUTED 2-AMINO-QUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2013-02-14 | — | — | WO | disclosed |
| US-20120220627-A1 | Substituted 2-amino-quinoline-3-carboxamides as KCNQ2/3 modulators | GRUNENTHAL GMBH (DE) | 2012-08-30 | — | — | US | disclosed |
| WO-2012025237-A1 | SUBSTITUTED 2-AMINO-QUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220627-A1 | Substituted 2-amino-quinoline-3-carboxamides as KCNQ2/3 modulators | KCNQ1, KCNQ2, KCNQ3 | CCR1 4620/4885MLYCD 3436/4885TACR1 2723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.